Wide Ranks

ANNX

Annexon, Inc.

5.34

Top Statistics
Market Cap 569 M Forward PE -4.97 Revenue Growth 0.00 %
Current Ratio 21.81 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.65 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 368 M Total Cash Per Share 3.49 Total Debt 30 M
Total Debt To Equity 8.37 Current Ratio 21.81 Book Value Per Share 3.20
All Measures
Short Ratio 677.00 % Message Board Id finmb_279883519 Fax 650 636 9773
Shares Short Prior Month 8 M Return On Equity -0.4220 City Brisbane
Uuid 39e86d0b-392a-371c-9e14-996bb9ee6158 Previous Close 5.29 First Trade Date Epoch Utc 1 B
Book Value 3.20 Beta 1.23 Total Debt 30 M
Volume 1 M Price To Book 1.67 Fifty Two Week Low 2.27
Total Cash Per Share 3.49 Shares Short Previous Month Date 1 B Target Median Price 12.50
Audit Risk 3 Max Age 86400 Recommendation Mean 1.43
Sand P52 Week Change 0.3133 Target Mean Price 15.00 Net Income To Common -115159000
Short Percent Of Float 0.0880 Implied Shares Outstanding 106 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 368 M Next Fiscal Year End 1 B Held Percent Insiders 0.0050
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 5.29 Target Low Price 9.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 6.68 Open 5.28
Free Cashflow -60814752 State CA Dividend Yield 0.00 %
Return On Assets -0.2483 Time Zone Short Name EST Board Risk 6
Trailing Eps -1.03 Day Low 5.27 Address1 1400 Sierra Point Parkway
Shares Outstanding 106 M Compensation Risk 9 Price Hint 2
Target High Price 30.00 Website https://www.annexonbio.com 52 Week Change 1.14
Average Volume 1 M Forward Eps -1.14 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 2150.10 % Is_sp_500 False
Regular Market Day High 5.50 Profit Margins 0.00 % Debt To Equity 8.37
Fifty Two Week High 8.40 Day High 5.50 Shares Short 7 M
Regular Market Open 5.28 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0735 Operating Cashflow -101744000
Currency USD Time Zone Full Name America/New_York Market Cap 569 M
Is_nasdaq_100 False Zip 94005 Quote Type EQUITY
Industry Biotechnology Long Name Annexon, Inc. Overall Risk 7
Regular Market Day Low 5.27 Held Percent Institutions 1.06 Current Price 5.34
Address2 Building C Suite 200 Enterprise To Ebitda -2.65 Financial Currency USD
Current Ratio 21.81 Industry Disp Biotechnology Number Of Analyst Opinions 6
Country United States Float Shares 68 M Two Hundred Day Average 5.82
Governance Epoch Date 1 B Enterprise Value 330 M Forward PE -4.97
Regular Market Volume 1 M Ebitda -124791000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.

In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.

The company was incorporated in 2011 and is headquartered in Brisbane, California.